DOCSLIB.ORG

Effects of Pitolisant, a Histamine H3 Inverse Agonist, in Drug-Resistant

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Pitolisant, a Histamine H3 Inverse Agonist, in Drug-Resistant Sleep Medicine 15 (2014) 681–687 Contents lists available at ScienceDirect Sleep Medicine journal homepage: www.elsevier.com/locate/sleep Original Article Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review ⇑ Smaranda Leu-Semenescu a,b,c, , Nandy Nittur b, Jean-Louis Golmard d, Isabelle Arnulf a,b,c a National Reference Centre for Narcolepsy and Idiopathic Hypersomnia, France b AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Service des Pathologies du Sommeil, Paris, France c Pierre and Marie Curie University, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, Inserm U 1127, CNRS UMR7225, Paris, France d Department of Biostatistics, Hôpital Universitaire Pitié-Salpêtrière, ER4, Pierre and Marie Curie University, Paris, France article info abstract Article history: Objective: To evaluate the benefits and risks of pitolisant (a wake-enhancing drug that increases the his- Received 13 September 2013 tamine release in the brain by blocking presynaptic H3 histamine reuptake) in patients with idiopathic Received in revised form 10 December 2013 (IH) and symptomatic (SH) hypersomnia plus sleepiness refractory to available stimulants (modafinil, Accepted 7 January 2014 methylphenidate, mazindol, sodium oxybate, and D-amphetamine). Available online 18 March 2014 Methods: Through retrospective analyses of patient files, the benefit (the score from the Epworth Sleep- iness Scale [ESS], authorization renewal) and tolerance (side-effects) of pitolisant were assessed. Keywords: Results: A total of 78 patients with IH (n = 65%, 78% women) and SH (n = 13%, 54% women) received pitol- Idiopathic hypersomnia isant 5–50 mg once per day over the course of five days to 37 months. The median (interquartile range) Pitolisant BF2.649 ESS scores of patients with IH decreased from 17 (15.5–18.5) to 14 (12–17). There were 36% responders H3 receptor antagonist (ESS fall of P3). The improvement in ESS score (À1.9 ± 2.6) was different from 0 in IH without long sleep Histamine time (P < 0.002) and in IH with a long sleep time (P < 0.0001), but not in SH. Forty-four (63%) patients Sleepiness with IH and 12 (77%) patients with SH stopped pitolisant, mostly due to a lack of efficacy. Side-effects included gastrointestinal pain (15.4%), increased appetite and weight gain (14.1%), headache (12.8%), insomnia (11.5%), and anxiety (9%), as well as exceptional reports of depression and persistent genital arousal. Conclusion: Pitolisant had a long-term favorable benefit/risk ratio in 23–38% of drug-resistant patients with IH and SH, suggesting that histamine neurons can be stimulated in severe idiopathic and symptom- atic hypersomnia. Ó 2014 Elsevier B.V. All rights reserved. 1. Introduction abnormally stimulated by an unknown endogenous substance in some cases [4]. Cerebrospinal fluid histamine levels are reduced Idiopathic hypersomnia (IH) is a rare (0.002–0.02% of the popu- [5,6] or unchanged in instances of IH [7], but they are also reduced lation) and disabling disease that affects mostly young subjects [1]. in narcolepsy with or without hypocretin deficiency, suggesting In addition to suffering from severe daytime sleepiness, most that low histamine levels signal rather than cause somnolence of patients report major sleep inertia, impaired daytime alertness a central origin. In addition to these idiopathic central hypersom- (the feeling of never being really awake), and altered cognition nias, some hypersomnias that are symptomatic of diencephalic with automatic behaviors [2,3]. Two forms of the disease are recog- lesions (e.g. neurolupus and craniopharyngioma) and medical dis- nized: one with and one without long (>10 h) night-time sleep. The eases have been described [1]. cause of this disease is unknown. The hypocretin system, which is Because IH is rare, no randomized controlled therapeutic trials deficient in narcolepsy/cataplexy, is unaffected in patients with IH, have been performed. As a consequence, no stimulant has received whereas the gamma-aminobutyric acid (GABA) system may be current approval from drug agencies for the purposes of treating IH. At present, clinicians treat IH-associated sleepiness with the same treatments as those used in narcolepsy [8]. Modafinil has a good benefit/risk ratio in IH with or without long sleep time, similar ⇑ Corresponding author at: Service des Pathologies du Sommeil, Hôpital Pitié Salpêtrière, 47-83 boulevard de l’Hôpital, 75651 Paris Cedex 13, France. Tel.: +33 to its effects in narcolepsy/cataplexy [9]. However, modafinil and 142167702; fax: +33 1 42167700. methylphenidate provide, at best, only moderate improvement in E-mail address: [email protected] (S. Leu-Semenescu). sleepiness in patients with IH [10]. Reports of sodium oxybate use http://dx.doi.org/10.1016/j.sleep.2014.01.021 1389-9457/Ó 2014 Elsevier B.V. All rights reserved. 682 S. Leu-Semenescu et al. / Sleep Medicine 15 (2014) 681–687 in IH are exceptional [10]. Plus, some patients have a severe sleepi- 2010 to March 2013 and who used the drug for at least a single ness refractory to these drugs and require another therapeutic day. To be eligible for an individual ATU of pitolisant, delivered option. Dextroamphetamine has been approved by the US Food by the French Drug Agency (Agence Nationale de Sécurité du and Drug Administration for the treatment of narcolepsy and is also Médicament et des produits de santé), the patients must have suf- used in patients with IH in the UK and the USA [10,11]. Pemoline has fered symptoms resistant to stimulants that were approved for been withdrawn from the market due to concerns about the risk of narcolepsy given at the highest tolerable dosage. In France, modafi- liver toxicity [10,12]. Mazindol and D-amphetamine can be obtained nil, methylphenidate and sodium oxybate are marketed for narco- in rare cases in France on a named patient basis after approval by the lepsy and can be used by analogy in primary and secondary French Drug Agency [13]. Although all of these treatments are active, hypersomnias of central origin. Mazindol [13] and D-amphetamine further medication improvements are needed in terms of efficacy, are imported on an individual basis and are delivered by the hos- ease of use, and safety. pital pharmacy after the ATU has been obtained. These criteria Pitolisant (BF 2.649, previously named tiprolisant; Bioprojet for eligibility are strict and must be approved by two anonymous Ltd., Paris, France) is a new histaminergic stimulant. This inverse experts in the field after they have reviewed the medical case. agonist of the histamine H3 autoreceptor increases histamine The individual ATU procedure is aimed at making some drugs release in the hypothalamus and cortex. Pitolisant increases wake- that are currently absent from the national market available to a fulness and decreases narcoleptic episodes in orexin knockout limited number of patients with resistant, severe and orphan dis- mice. In a single-blind trial, it reduced excessive daytime sleepi- eases for the sake of human compassion. This procedure requires ness in patients with narcolepsy/cataplexy [14]. In a recent large, the treating physician (who should be experienced in the field randomized controlled study of pitolisant (versus modafinil and and a member of a sleep center in a university hospital) to com- versus placebo) in 95 patients with narcolepsy, the Epworth Sleep- plete a detailed, anonymous form listing the patient’s age, sex, iness Scale (ESS) score improved by À5.8 with pitolisant, a weight, diagnosis, medical history, severity of the disease, and list decrease which was non-inferior to modafinil [15]. We first of maximum dosages and effects (benefit and side-effects) of drugs reviewed the charts of four teenagers with resistant narcolepsy already used to alleviate sleepiness along with the reason for who benefited from pitolisant treatment [16]. Since 2010, because requesting the authorization. The form is sent to the drug agency the drug had been tested in phase III trials and one long-term via the local hospital pharmacy and examined by two anonymous open-extension trial for narcolepsy, it was available on a named expert referees (one physician and one pharmacist) who decide patient basis to patients with IH experiencing severe sleepiness whether to authorize the administration of the drug for three refractory to available stimulants after individual authorization months. In particular, they require the knowledge of whether the from the French Drug Agency. We studied the benefits and risks maximum stimulant dosages have been tried in these patients of pitolisant in our patients with IH and symptomatic hypersomnia and whether intolerable side-effects were observed. Their decision over the long term using a chart review process. is based on a major resistance to marketed drugs given at the high- est tolerated dosage. If refractory sleepiness is the motive for requesting pitolisant, then the symptoms should be refractory to 2. Methods modafinil 600 mg/day, methylphenidate 80 mg/day, and sodium oxybate 9 g/day alone or in combination. The liability is shared 2.1. Subjects between the French Drug Agency and the physician prescribing the non-marketed drug (who engages his or her liability with a The files of all patients diagnosed with IH and symptomatic written signature). Every three months, the physician must report hypersomnia at the University Hospital of Pitié-Salpêtrière (Paris) on the benefits and side-effects of the drug to the agency through a and treated with pitolisant were retrospectively collected. The form and dependening on this information, can obtain a renewal of study was approved by the local institutional review board. All of the authorization for use. The hospital pharmacy buys the drug the patients had undergone an attended nocturnal polysomnogra- from the pharmaceutical company and sells it directly to the phy followed by five multiple sleep latency tests (MSLTs) the next patient, and the price is paid by the national health insurance.
Load more

Recommended publications
  • Pharmacy Policy Statement
    PHARMACY POLICY STATEMENT Georgia Medicaid DRUG NAME Wakix (pitolisant) BILLING CODE Must use valid NDC BENEFIT TYPE Pharmacy SITE OF SERVICE ALLOWED Home COVERAGE REQUIREMENTS Prior Authorization Required (Non-Preferred Product) QUANTITY LIMIT— 60 tablets per 30 days LIST OF DIAGNOSES CONSIDERED NOT Click Here MEDICALLY NECESSARY Wakix (pitolisant) is a non-preferred product and will only be considered for coverage under the pharmacy benefit when the following criteria are met: Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated. NARCOLEPSY WITH EXCESSIVE DAYTIME SLEEPINESS (EDS) For initial authorization: 1. Member is 18 years old or older; AND 2. Medication must be prescribed by or in consultation with a neurologist or sleep specialist; AND 3. Member has a diagnosis of narcolepsy confirmed by sleep studies: polysomnogram and MSLT (multiple sleep latency test); AND 4. Member has symptoms of excessive sleepiness not attributed to other factors such as insufficient sleep, irregular sleep schedule, co-existent sleep disorder, medications or other substances; AND 5. Member’s current score on the Epworth sleepiness scale (ESS) is documented in chart notes; AND 6. Member has tried and failed or did not tolerate the following, at max tolerated dose, for at least 30 days each: modafinil or armodafinil, AND Sunosi; AND 7. Member does not have ANY of the following: a) Severe hepatic impairment; b) End stage renal disease; c) QT interval prolongation or cardiac arrythmia. 8. Dosage allowed: Up to 2 tablets per day; max daily dose of 35.6mg (Two 17.8mg tablets once daily).
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Neuroenhancement in Healthy Adults, Part I: Pharmaceutical
    l Rese ca arc ni h li & C f B o i o l e Journal of a t h n Fond et al., J Clinic Res Bioeth 2015, 6:2 r i c u s o J DOI: 10.4172/2155-9627.1000213 ISSN: 2155-9627 Clinical Research & Bioethics Review Article Open Access Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review Fond G1,2*, Micoulaud-Franchi JA3, Macgregor A2, Richieri R3,4, Miot S5,6, Lopez R2, Abbar M7, Lancon C3 and Repantis D8 1Université Paris Est-Créteil, Psychiatry and Addiction Pole University Hospitals Henri Mondor, Inserm U955, Eq 15 Psychiatric Genetics, DHU Pe-psy, FondaMental Foundation, Scientific Cooperation Foundation Mental Health, National Network of Schizophrenia Expert Centers, F-94000, France 2Inserm 1061, University Psychiatry Service, University of Montpellier 1, CHU Montpellier F-34000, France 3POLE Academic Psychiatry, CHU Sainte-Marguerite, F-13274 Marseille, Cedex 09, France 4 Public Health Laboratory, Faculty of Medicine, EA 3279, F-13385 Marseille, Cedex 05, France 5Inserm U1061, Idiopathic Hypersomnia Narcolepsy National Reference Centre, Unit of sleep disorders, University of Montpellier 1, CHU Montpellier F-34000, Paris, France 6Inserm U952, CNRS UMR 7224, Pierre and Marie Curie University, F-75000, Paris, France 7CHU Carémeau, University of Nîmes, Nîmes, F-31000, France 8Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany *Corresponding author: Dr. Guillaume Fond, Pole de Psychiatrie, Hôpital A. Chenevier, 40 rue de Mesly, Créteil F-94010, France, Tel: (33)178682372; Fax: (33)178682381; E-mail: [email protected] Received date: January 06, 2015, Accepted date: February 23, 2015, Published date: February 28, 2015 Copyright: © 2015 Fond G, et al.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Pitolisant and Other Histamine-3 Receptor Antagonists—An Update on Therapeutic Potentials and Clinical Prospects
    medicines Review Pitolisant and Other Histamine-3 Receptor Antagonists—An Update on Therapeutic Potentials and Clinical Prospects Victoria Harwell and Pius S. Fasinu * Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Campbell University, Buies Creek, NC 27501, USA; [email protected] * Correspondence: [email protected] Received: 28 July 2020; Accepted: 27 August 2020; Published: 1 September 2020 Abstract: Background: Besides its well-known role as a peripheral chemical mediator of immune, vascular, and cellular responses, histamine plays major roles in the central nervous system, particularly in the mediation of arousal and cognition-enhancement. These central effects are mediated by the histamine-3 auto receptors, the modulation of which is thought to be beneficial for the treatment of disorders that impair cognition or manifest with excessive daytime sleepiness. Methods: A database search of PubMed, Google Scholar, and clinicaltrials.gov was performed in June 2020. Full-text articles were screened and reviewed to provide an update on pitolisant and other histamine-3 receptor antagonists. Results: A new class of drugs—histamine-3 receptor antagonists—has emerged with the approval of pitolisant for the treatment of narcolepsy with or without cataplexy. At the recommended dose, pitolisant is well tolerated and effective. It has also been evaluated for potential therapeutic benefit in Parkinson disease, epilepsy, attention deficit hyperactivity disorder, Alzheimer’s disease, and dementia. Limited
    [Show full text]
  • Neue Wirkstoffkandidaten Mit Histamin-H3- Rezeptor-Pharmakophor Auf Dem Gebiet
    Neue Wirkstoffkandidaten mit Histamin-H3- Rezeptor-Pharmakophor auf dem Gebiet neurodegenerativer Erkrankungen Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf vorgelegt von Markus Martin Falkenstein aus Bochum Düsseldorf, März 2021 aus dem Institut für Pharmazeutische und Medizinische Chemie der Heinrich-Heine-Universität Düsseldorf Gedruckt mit der Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Berichterstatter: 1. Univ.-Prof. Dr. Dr. hc. Holger Stark 2. Univ.-Prof. Dr. Thomas Kurz Tag der mündlichen Prüfung: 26.05.2021 Danksagung Ich bin stolz und glücklich, mich bei meinem Doktorvater Herrn Prof. Dr. Dr. Holger Stark bedanken zu können. Ich bedanke mich für die Möglichkeit der Promotion in seinem Arbeitskreis am Institut für Medizinische und Pharmazeutische Chemie der Heinrich-Heine- Universität Düsseldorf und für das äußerst interessante Thema, das ich während meiner Promotion bearbeiten konnte. Ich bedanke mich für einen regen wissenschaftlichen Austausch, fachliche Expertise, konstruktive Diskussionen und Hilfestellung. Des Weiteren bedanke ich mich für hilfreiche Gespräche auch abseits von Wissenschaft und Forschung. Ich bedanke mich bei Herrn Prof. Dr. Thomas Kurz, der mit als Co-Betreuer und Zweitkorrektor jederzeit für einen konstruktiven Austausch zur Verfügung stand. Ich bedanke mich bei meinem Arbeitskreis, der mir in wechselnder Zusammensetzung sowohl fachlich als auch privat einen großen Rückhalt geboten hat. Im Besonderen bedanke ich mich bei Frau Annika Frank, Frau Kathrin Grau und Herrn David Reiner-Link für die pharmakologische Charakterisierung meiner Substanzen. In diesem Zusammenhang danke ich auch Prof. Wieslawa Agnieszka Fogel und ihrem Arbeitskreis im Dept. of Hormone Biochemistry, Medical University of Łodz, Polen für die Bestimmung der ZNS-Gängigkeit in In-vivo-Experimenten.
    [Show full text]
  • Wakix (Pitolisant) C17997-A
    Prior Authorization Criteria Wakix (pitolisant) Policy Number: C17997-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DUE BY OR BEFORE 02/01/2020 1/21/2021 4/2022 J CODE TYPE OF CRITERIA LAST P&T APPROVAL/VERSION NA RxPA Q2 2021 20210428C17997-A PRODUCTS AFFECTED: Wakix (pitolisant) DRUG CLASS: Histamine H3-Receptor Antagonist/Inverse Agonists ROUTE OF ADMINISTRATION: Oral PLACE OF SERVICE: Specialty Pharmacy The recommendation is that medications in this policy will be for pharmacy benefit coverage and patient self-administered AVAILABLE DOSAGE FORMS: Wakix TABS 4.45MG, Wakix TABS 17.8MG (bottles of 30) FDA-APPROVED USES: indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy COMPENDIAL APPROVED OFF-LABELED USES: None COVERAGE CRITERIA: INITIAL AUTHORIZATION DIAGNOSIS: excessive daytime sleepiness (EDS) with narcolepsy REQUIRED MEDICAL INFORMATION: A. EXCESSIVE DAYTIME SLEEPINESS WITH NARCOLEPSY: 1. Prescriber attests that member meets the International Classification of Sleep Disorders Third Edition and the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (ICSD-3 and DSM-5) guidelines for diagnosis of: (a) Narcolepsy Type 2 (narcolepsy without cataplexy) [i. An overnight polysomnogram followed the next day by an MSLT that demonstrates a mean sleep latency ≤ 8 minutes and at least two SOREMPs. OR (b) prescriber attests based on clinical judgement the member has symptoms suggestive of REM sleep dysfunction (e.g. frequent sleep paralysis or hypnagogic hallucinations) Molina Healthcare, Inc. confidential and proprietary © 2021 This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare.
    [Show full text]
  • Summary of the Risk Management Plan (RMP) for Wakix (Pitolisant)
    EMA/794885/2015 Summary of the risk management plan (RMP) for Wakix (pitolisant) This is a summary of the risk management plan (RMP) for Wakix, which details the measures to be taken in order to ensure that Wakix is used as safely as possible. For more information on RMP summaries, see here. This RMP summary should be read in conjunction with the EPAR summary and the product information for Wakix, which can be found on Wakix’s EPAR page. Overview of disease epidemiology Wakix (pitolisant) is a medicine used to treat narcolepsy. Narcolepsy is a rare, long-term sleep disorder which affects the brain’s ability to regulate the normal sleep-wake cycle. Narcolepsy is characterised by excessive daytime sleepiness, episodes of muscle weakness (cataplexy), hallucinations related to sleep, sleep paralysis, broken sleep at night, reduced attention span as well as non-sleep symptoms such as obesity, anxiety, and cognitive and emotional problems. Not all symptoms are present in all patients. The prevalence of narcolepsy in European countries varies from 2 to 5 people in 10,000. The age of onset varies from early childhood to around 50 years. Summary of treatment benefits Wakix has been investigated in 2 main studies involving a total of 261 adults with narcolepsy, the majority of whom also had cataplexy. The studies compared Wakix with placebo (a dummy treatment). The main measure of effectiveness was based on how sleepy patients felt during daytime, assessed using the Epworth Sleepiness Scale or ESS. This is a standard scale used in patients with narcolepsy which ranges from 0 to 24.
    [Show full text]
  • New Medicine Recommendation Pitolisant 4.5Mg/18Mg Tablets (Wakix®) for Treatment of Narcolepsy with Or Without Cataplexy in Adults
    New Medicine Recommendation Pitolisant 4.5mg/18mg tablets (Wakix®) For Treatment of Narcolepsy with or without Cataplexy in adults Recommendation: Black Pitolisant tablets are not recommended for use across the Lancashire NHS health economy for the treatment of narcolepsy with or without cataplexy. Pitolisant did not demonstrate non- inferiority compared to modafinil and is significantly more expensive than other treatments available in Lancashire for the management of narcolepsy with or without cataplexy. Summary of supporting evidence: In the Harmony I study, the primary analysis of between-group differences in mean Epworth Sleepiness Scale (ESS) score at endpoint (adjusted for baseline) showed pitolisant to be superior to placebo (difference –3·0, [CI95% –5·6; –0·4, p=0·024]). The non-inferiority of pitolisant compared to modafinil was not demonstrated in both the Harmony I and Harmony Ibis Studies. In the Harmony CTP study, pitolisant produced significant improvements in the weekly cataplexy rate (WCR), decreasing from 7.31 to 6.79 for placebo and 9.15 to 3.28 for pitolisant, with a ratio rate (Pitolisant/Placebo) = 0.512 [CI95% 0.435; 0.603, p<0.0001]). The EMEA stated that, based on available data, the safety profile of pitolisant in the treatment of narcolepsy with or without cataplexy is acceptable. However, the EMEA also noted that the long-term safety database for pitolisant in narcolepsy patients is limited. Treatment should be initiated, evaluated and discontinued in secondary care by a clinician experienced in the treatment of sleep disorders. There are limited safe and well tolerated treatment options for the management of narcolepsy with cataplexy.
    [Show full text]
  • Histamine Receptor
    Histamine Receptor Histamine Receptors are a class of G protein-coupled receptors with histamine as their endogenous ligand. There are four known histamine receptors: H1 receptor, H2 receptor, H3 receptor, H4 receptor. The H1 receptor is a histamine receptor belonging to the family of Rhodopsin-like G-protein-coupled receptors. This receptor, which is activated by the biogenic amine histamine, is expressed throughout the body, to be specific, in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. H2 receptors are positively coupled to adenylate cyclase via Gs. It is a potent stimulant of cAMP production, which leads to activation of Protein Kinase A. Histamine H3 receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act asautoreceptors in presynaptic histaminergic neurons, and also control histamine turnover by feedback inhibition of histamine synthesis and release. The Histamine H4 receptor has been shown to be involved in mediating eosinophil shape change and mast cell chemotaxis. www.MedChemExpress.com 1 Histamine Receptor Inhibitors & Modulators (±)-Methotrimeprazine (D6) (±)-Tazifylline (dl-Methotrimeprazine D6) Cat. No.: HY-19489S Cat. No.: HY-U00018 Bioactivity: (±)-Methotrimeprazine (D6) is the deuterium labeled Bioactivity: (±)-Tazifylline is a potent, selective and long-acting Methotrimeprazine, which is a D3 dopamine and Histamine H1 histamine H1 receptor antagonist. receptor antagonist. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg Size: 1 mg, 5 mg, 10 mg, 20 mg ABT-239 Acrivastine Cat. No.: HY-12195 (BW825C) Cat. No.: HY-B1510 Bioactivity: ABT-239 is a novel, highly efficacious, Bioactivity: Acrivastine (BW825C) is a short acting histamine 1 non-imidazole class of H3R antagonist and a transient receptor antagonist for the treatment of allergic rhinitis.
    [Show full text]